Bristol Myers Squibb (BMY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Research Workspace
Put BMY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue is growing steadily — about 3% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 12%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskHealthy across the board
Bristol Myers Squibb's growth potential hinges on its recent FDA approvals and pipeline advancements. Revenue grew 6% year over year, and the last quarter beat expectations. It trades at 10× P/E versus a peer median of 16×, indicating the price reflects less growth than forecasted. Specific risks include a potential credibility hit if guidance is cut after a recent raise, with an 11% miss probability for the next quarter. Peer multiples imply a price about 6% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. BMY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering BMY (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for BMY in the last 4 months.
Continue this research
Compare BMY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BMY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Compare the value case
Put BMY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
ZENBEXUS approval supports pipeline advancement and growth potential.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $66.82
The last 12 months of price, then the range of analyst 12-month targets from today’s $66.82.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Advance pipeline with high-impact transformational medicines
AI antibody deal enhances pipeline advancement potential.

Lawsuit could impact financial stability and growth objectives.

Advances: Raise full-year revenue and EPS guidance for 2026
FDA approval supports revenue and EPS guidance for 2026.

Lawsuit could delay drug pipeline advancements.

Lawsuit could delay drug pipeline advancements.

Lawsuit could delay drug pipeline advancements.

AI overhaul and oncology trials enhance growth potential.